ライフサイエンスコーパス: diabetes mellitus

1 ors (hypercholesterolemia, hypertension, and diabetes mellitus).

2 ch for reducing excess glucose production in diabetes mellitus.

3 used to assess risk factors for undiagnosed diabetes mellitus.

4 ng target for beta-cell protection in type 1 diabetes mellitus.

5 Overall, 1134 of 4128 patients (27%) had diabetes mellitus.

6 the potential to attenuate hyperglycemia in diabetes mellitus.

7 ising strategies for the treatment of type 2 diabetes mellitus.

8 t admission were associated with undiagnosed diabetes mellitus.

9 r and cardiovascular complications in type 2 diabetes mellitus.

10 ilure at time of transplant, with or without diabetes mellitus.

11 10.4; P=0.010) were higher in patients with diabetes mellitus.

12 chronic kidney disease, obesity, and type 2 diabetes mellitus.

13 y artery disease, blood pressure, lipids, or diabetes mellitus.

14 Fifteen percent of patients had known diabetes mellitus.

15 ble vision respectively, as complications of diabetes mellitus.

16 lence of elevated predicted cardiac risk and diabetes mellitus.

17 essential indicators of glycemic control for diabetes mellitus.

18 llitus was high compared to patients without diabetes mellitus.

19 s and left atrial area than patients without diabetes mellitus.

20 major cause of vision loss in patients with diabetes mellitus.

21 nique in vitro system emulating human type 2 diabetes mellitus.

22 of, and outcomes in, those with and without diabetes mellitus.

23 risk factors for cardiovascular disease and diabetes mellitus.

24 Incident type 2 diabetes mellitus.

25 f tighter BP control in patients with Type 2 diabetes mellitus.

26 (HbA1c) is accordingly examined for checking diabetes mellitus.

27 etic retinopathy is a common complication of diabetes mellitus.

28 ncountered by patients suffering from type 2 Diabetes Mellitus.

29 y and contribute to microvascular disease in diabetes mellitus.

30 ns and supplies as a measure of postdonation diabetes mellitus.

31 ta cell function underlies type 1 and type 2 diabetes mellitus.

32 ratified according to presence or absence of diabetes mellitus.

33 n particular for cardiovascular diseases and diabetes mellitus.

34 consumption in people with type 1 and type 2 diabetes mellitus.

35 n improved treatment of patients with type 1 diabetes mellitus.

36 as also associated with a small reduction in diabetes mellitus.

37 apy for hypertension in patients with Type 2 diabetes mellitus.

38 d Ejection Fraction) according to history of diabetes mellitus.

39 30 and 121 osteoporosis/fractures, 82 and 94 diabetes mellitus, 114 and 129 cardiovascular events, 11

40 mortality rate compared to patients without diabetes mellitus (12.1% vs 3.8%, respectively; P = .001

41 5% versus 31%), and had a longer duration of diabetes mellitus (14 versus 13 years) compared with sec

42 g whites and 72% (68%-78%) among blacks; for diabetes mellitus, 14% (10%-20%) among whites and 31% (2

43 Prevalence of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.7%-19.5

44 ute kidney injury had a higher prevalence of diabetes mellitus (21.2% vs 9.8%; p < 0.001) and hyperte

45 rs for HF were common: hypertension (62.5%), diabetes mellitus (26.5%), myocardial infarction (8.6%),

46 isease (51.5%), renal insufficiency (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary

47 3.0 (heart failure, 1.4%; hypertension, 54%; diabetes mellitus, 30%; prior stroke/transient ischemic

48 Comorbidities included hypertension (77%), diabetes mellitus (31%), and coronary artery disease (15

49 ristics were similar between groups: 50% had diabetes mellitus, 41% were women, mean lesion length wa

50 Among patients without known diabetes mellitus, 5.0% had undiagnosed diabetes mellitu

51 nformation revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73%

52 white, primarily black; 25% had a history of diabetes mellitus, 59% hypertension, 55% dyslipidemia, a

53 Diabetes mellitus (60%) and hypertension (15%) were the

54 ed by sepsis (8.3%) and complications due to diabetes mellitus (7.5%).

55 y promote bone repair in a leporine model of diabetes mellitus, a condition that is known to be detri

56 underlying bone impairment in patients with diabetes mellitus, a metabolic disorder characterized by

57 t-amyloid polypeptide associated with type 2 diabetes mellitus, a-synuclein associated with Parkinson

58 iabetes mellitus versus 22% of those without diabetes mellitus (adjusted hazard ratio, 1.75; 95% conf

59 ntravenous central lines, urinary catheters, diabetes mellitus, AIDS, end-stage renal disease, and ci

60 In participants without diabetes mellitus, allopurinol associated with a trend t

61 res of insulin resistance, dyslipidemia, and diabetes mellitus also were associated with distinct asp

62 ed beta-cell dysfunction and death in type 1 diabetes mellitus, although the mechanisms are incomplet

63 ary atherosclerosis in prediabetes and early diabetes mellitus among men.

64 nown diabetes mellitus, 5.0% had undiagnosed diabetes mellitus and 37.5% had prediabetes.

65 Overall, 2074 of 33 333 patients with diabetes mellitus and 4141 of 166 529 controls died.

66 e compared with 82 control patients (32 with diabetes mellitus and 50 with nondiabetic kidney disease

67 h an index pregnancy affected by gestational diabetes mellitus and 626 controls enrolled in the Danis

68 the most widely used therapeutics for type 2 diabetes mellitus and also has anticancer and antiaging

69 o have had an HF hospitalization, orthopnea, diabetes mellitus and anemia, be treated with beta-block

70 Overall, 29.9% of patients with diabetes mellitus and cardiovascular disease achieved al

71 econdary prevention care among patients with diabetes mellitus and cardiovascular disease, which in t

72 ficantly improves outcomes for patients with diabetes mellitus and cardiovascular disease.

73 ally is associated with morbidity related to diabetes mellitus and cardiovascular diseases.

74 ed more often, and had a higher frequency of diabetes mellitus and cardiovascular events.

75 , or nonfatal stroke in patients with type 2 diabetes mellitus and elevated cardiovascular risk.

76 bidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease

77 The mechanisms underlying the progression of diabetes mellitus and heart failure are closely intertwi

78 onary artery disease and major risk factors (diabetes mellitus and hypertension).

79 e older and plagued by comorbidities such as diabetes mellitus and hypertension.

80 associated with age, body mass index, type 2 diabetes mellitus and inversely with estimated glomerula

81 We aimed to assess the risk of developing diabetes mellitus and its effects on all-cause mortality

82 The incidence of diabetes mellitus and its mortality were assessed using

83 among 13 616 patients from 38 countries with diabetes mellitus and known cardiovascular disease at en

84 l in real-world practice among patients with diabetes mellitus and MV-CAD in residents of British Col

85 ed events, but also with a reduced hazard of diabetes mellitus and possibly of chronic renal failure.

86 linical indications, including patients with diabetes mellitus and prediabetes and those with high ri

87 monia, whereas the prevalence of undiagnosed diabetes mellitus and prediabetes in patients with commu

88 ntensive risk factor management, people with diabetes mellitus and prediabetes remain at increased co

89 The prevalence of undiagnosed diabetes mellitus and prediabetes was estimated based on

90 in secondary prevention among patients with diabetes mellitus and prediabetes, patients at high risk

91 Patients with type 2 diabetes mellitus and prior cardiovascular events had hi

92 Diabetes mellitus and smoking were not associated with L

93 hyperlipidemia, 1.01 (95% CI: 0.89-1.15) for diabetes mellitus, and 1.19 (95% CI: 1.08-1.32) for curr

94 Overall, mean age was 63.4 years, 32.5% had diabetes mellitus, and 39.7% presented with acute corona

95 ody mass index, hypertension, renal disease, diabetes mellitus, and AS severity.

96 tes, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascular disease.

97 c hypertension, hypercholesterolemia, type 2 diabetes mellitus, and changes in body mass index (propo

98 patients had higher risks of obesity, type 2 diabetes mellitus, and circulatory system diseases.

99 ory characteristics, including hypertension, diabetes mellitus, and coronary artery disease.

100 notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyositis, as well as monog

101 atrial fibrillation, chronic kidney disease, diabetes mellitus, and dyslipidemia, and had more often

102 tes of comorbidities (arterial hypertension, diabetes mellitus, and heart failure), and a lower risk

103 e, history of hypertension, current smoking, diabetes mellitus, and lipid profile, the former NFL ath

104 Primary outcomes were CHD, type 2 diabetes mellitus, and major stroke subtypes; secondary

105 yopathy, hypertension, ischemia, thrombosis, diabetes mellitus, and migraine.

106 phic cardiomyopathy, ischemic heart disease, diabetes mellitus, and more.

107 in, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfinavir, an HIV protease inhib

108 and income level), alcohol and tobacco use, diabetes mellitus, and past periodontal treatment (model

109 terol), and clinical variables (C) (smoking, diabetes mellitus, and peripheral arterial disease).

110 r, and had lower prevalence of hypertension, diabetes mellitus, and renal impairment (but had higher

111 e the prevalence of prediabetes, undiagnosed diabetes mellitus, and risk factors associated with undi

112 such as hypercholesterolemia, hypertension, diabetes mellitus, and smoking enhance ROS generation an

113 aphic disparities in prevalent hypertension, diabetes mellitus, and smoking exist within states and w

114 variation in the prevalence of hypertension, diabetes mellitus, and smoking within and across US coun

115 ry artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascula

116 okine abnormalities (the hallmarks of type 2 diabetes mellitus) are characteristic features of heart

117 nical candidates for the treatment of type 2 diabetes mellitus, as well as a promising starting point

118 erosis, hypertension, renal dysfunction, and diabetes mellitus; as a result, they offer insights into

119 Anonymized data of 50 254 patient eyes with diabetes mellitus at 19 UK hospital eye services were ex

120 We ascertained cases of type 1 and type 2 diabetes mellitus at five study centers in the United St

121 izing preventive strategies in patients with diabetes mellitus based on risk.

122 ncreatic ductal adenocarcinoma (PDA) develop diabetes mellitus before their cancer diagnosis.

123 For type 2 diabetes mellitus, both measures had large effects: OR,

124 on of this hormone is dysregulated in type 2 diabetes mellitus but the mechanisms controlling secreti

125 a for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subg

126 n glucose tolerance and the complications of diabetes mellitus by interfering with the actions of NHE

127 ients had higher prevalence of hypertension, diabetes mellitus, cardiac, peripheral vascular and chro

128 Diabetes mellitus causes microcirculatory rarefaction an

129 nown coronary artery disease, heart failure, diabetes mellitus, chronic kidney disease, anemia, coagu

130 The NLR-NAR events analyzed included diabetes mellitus, chronic renal failure, cardiovascular

131 e; venous thromboembolism; hypertension; and diabetes mellitus, comparing women who received fertilit

132 Diabetes mellitus compromises CMSC function as consequen

133 r glycated hemoglobin A1c testing for type 2 diabetes mellitus could be improved to bring them in lin

134 Diabetes mellitus destabilized microvascular vessels of

135 discrimination is related to incident type 2 diabetes mellitus (diabetes).

136 of HealthLNK for hypertension, obesity, and diabetes mellitus diagnosis by using International Class

137 c screening begin 3 to 5 years after initial diabetes mellitus diagnosis, at which point in our study

138 ictors were age and calendar year at initial diabetes mellitus diagnosis, sex, race/ethnicity, net wo

139 28% versus 19% of patients with and without diabetes mellitus died (adjusted hazard ratio, 1.59; con

140 The prevalences of PDAC signals, such as diabetes mellitus (DM) and chronic pancreatitis, were co

141 ffects of long-term periodontal infection on diabetes mellitus (DM) control.

142 mains higher in patients with versus without diabetes mellitus (DM) despite statin therapy.

143 ontrol group (n = 18) and an alloxan-induced diabetes mellitus (DM) group (n = 18).

144 table coronary artery disease, patients with diabetes mellitus (DM) have less angina and more silent

145 very following spinal cord injury (SCI), and diabetes mellitus (DM) impairs endothelial cell function

146 Comorbid diabetes mellitus (DM) increases tuberculosis (TB) risk

147 Diabetes mellitus (DM) is a risk factor for morbidity an

148 Diabetes mellitus (DM) is associated with increased mort

149 Diabetes mellitus (DM) remains a major health care probl

150 ronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control.

151 ed the first documented occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (CKD), an

152 ve been associated with an increased risk of diabetes mellitus (DM), whereas the association with art

153 ment for demographic variables, smoking, and diabetes mellitus (DM).

154 l activity were impaired in individuals with diabetes mellitus (DM).

155 g diabetes mellitus in NET patients, whereas diabetes mellitus does not appear to increase the mortal

156 the association of age, sex, smoking status, diabetes mellitus, educational level, alcohol consumptio

157 on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, a

158 Patients with type 2 diabetes mellitus, established cardiovascular disease, a

159 mortality in vulnerable patients with type 2 diabetes mellitus, established cardiovascular disease, a

160 eline, of whom 67% had a diagnosis of type 2 diabetes mellitus for >10 years, 58% were receiving insu

161 ed to monitor other complex diseases such as diabetes mellitus for better management and diagnostic p

162 TROKE (12 389 ischemic stroke cases), type 2 diabetes mellitus from DIAGRAM (Diabetes Genetics Replic

163 omen; 31.2% blacks) with hypertension but no diabetes mellitus from the SPRINT trial (Systolic Blood

164 The conjoint association of gestational diabetes mellitus (GDM) and gestational hypertension (GH

165 MP-1) in biofluids of women with gestational diabetes mellitus (GDM) and systemically healthy counter

166 Gestational diabetes mellitus (GDM) is conventionally confirmed with

167 le of iron in the development of gestational diabetes mellitus (GDM), a common pregnancy complication

168 examined the association between gestational diabetes mellitus (GDM), a state of transient hyperglyce

169 ired glucose tolerance (IGT) and gestational diabetes mellitus (GDM), and we used linear regression m

170 iomarkers among women with prior gestational diabetes mellitus (GDM).

171 widely observed in patients with gestational diabetes mellitus (GDM).

172 hat oversampled pregnancies with gestational diabetes mellitus (GDM).Six hundred eight women with an

173 risk children born to women with gestational diabetes mellitus (GDM).The analysis included 918 mother

174 hy behaviors and reduced risk of gestational diabetes mellitus (GDM); however, the association of com

175 Patients with diabetes mellitus had a greater left ventricular mass an

176 Patients with undiagnosed diabetes mellitus had a higher 180-day mortality rate co

177 Diabetes mellitus has become one of the biggest medical

178 h preserved ejection fraction, patients with diabetes mellitus have more signs of congestion, worse q

179 s (DFUs), a life-threatening complication of diabetes mellitus, have limited treatment options, often

180 val was similar in patients with and without diabetes mellitus (hazard ratio, 1.13; 95% confidence in

181 baseline systolic blood pressure, history of diabetes mellitus, history of smoking, elevated triglyce

182 Exclusion criteria were diabetes mellitus, history of stroke, >1 g proteinuria,

183 major side effects is the increased risk of diabetes mellitus; however, the exact mechanisms underly

184 rment were more likely to have hypertension, diabetes mellitus, hyperlipidaemia, prior stroke, lacune

185 , and cardiovascular risk factors, including diabetes mellitus, hyperlipidemia, and cigarette smoking

186 atients were younger and more likely to have diabetes mellitus, hypertension, and hyperlipidemia and

187 Weight, remission of type 2 diabetes mellitus, hypertension, dyslipidemia, depressio

188 s index, sex, coronary artery calcium score, diabetes mellitus, hypertension, hypercholesterolemia, f

189 Diabetes mellitus, hypertension, metabolic syndrome, smo

190 re tested in each of 12 patients with type 1 diabetes mellitus in a clinical set-up for 12h.

191 and risk factors associated with undiagnosed diabetes mellitus in a large European community-acquired

192 ups at baseline; 61% of the participants had diabetes mellitus in both groups.

193 Diabetes mellitus in early pregnancy can cause neural tu

194 ot appear to increase the risk of developing diabetes mellitus in NET patients, whereas diabetes mell

195 hanism underlying the increased incidence of diabetes mellitus in patients treated with this drug.

196 o a broad population of patients with type 2 diabetes mellitus in real-world practice.

197 After treatment, 72 patients developed diabetes mellitus, including 47 cases after (90)Y-DOTATO

198 ted phenotypes, including central adiposity, diabetes mellitus, insulin resistance, and circulating a

199 Among patients with hypertension but no diabetes mellitus, intensive BP lowering (target systoli

200 d death (IRR, 3.29 [95% CI, 1.35-8.05]), and diabetes mellitus (IRR, 4.62 [95% CI, 1.53-13.96]).

201 Type 1 diabetes mellitus is a chronic autoimmune disease that r

202 Type 2 diabetes mellitus is a complex disease affecting almost

203 Diabetes mellitus is an important risk factor for commun

204 Diabetes mellitus is associated with an increased risk f

205 BACKGROUND AND AIMS: Diabetes mellitus is likely to have a major effect on vi

206 and control groups in terms of hypertension, diabetes mellitus, ischaemic heart disease and hyperlipi

207 ially unchanged on additional adjustment for diabetes mellitus, ischemic heart disease, and hypertens

208 ys for each of 186 condition categories (eg, diabetes mellitus, ischemic heart disease, liver disease

209 ts were more likely to be younger, men, have diabetes mellitus, ischemic heart disease, lower left ve

210 left ventricular ejection fraction; more had diabetes mellitus, kidney disease, cardiac resynchroniza

211 Drugs used to treat diabetes mellitus may favorably affect the pathophysiolo

212 Rate ratios were adjusted for covariates (diabetes mellitus, myocardial infarction, stroke, and ve

213 Neonatal diabetes mellitus (NDM) is a rare form of diabetes diagn

214 a wide variety of human diseases, including diabetes mellitus, neurodegeneration, and cancer, thus o

215 lure, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, and elevated concentrati

216 ood pressure, lipids, insulin resistance and diabetes mellitus, nonalcoholic fatty liver disease, and

217 of sugar is associated with obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and

218 rdiovascular risk factors (eg, hypertension, diabetes mellitus, obesity, and atherosclerotic cardiova

219 /-14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hypertension increased.

220 clude sedentary lifestyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea, and elevated

221 nsion (odds ratio, 1.64; 95% CI, 1.11-2.43), diabetes mellitus (odds ratio, 1.88; 95% CI, 1.19-2.99),

222 sms with proinsulin misfolding in hereditary diabetes mellitus of youth.

223 st hoc analysis in 1147 patients with type 2 diabetes mellitus on hemodialysis who participated in th

224 rmine the mediators of the adverse impact of diabetes mellitus on outcomes in heart failure with pres

225 Evascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Di

226 Evascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel dis

227 evascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Dis

228 e of gingival connective tissues affected by diabetes mellitus or aging.

229 g older adults, young adults, and those with diabetes mellitus or chronic kidney disease.

230 tients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C >/

231 ncluding systolic blood pressure, history of diabetes mellitus or peripheral vascular disease, primar

232 or metabolic factors; by the development of diabetes mellitus; or by use/nonuse of statin therapy.

233 ese and therefore can expect higher rates of diabetes mellitus, other obesity-related comorbidities,

234 concentrations of glyoxal are elevated in in diabetes mellitus patients compared to nondiabetics.

235 August 2013 till July 2015 involving type 2 diabetes mellitus patients with no diabetic retinopathy

236 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant red

237 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

238 r cost with ezetimibe therapy, patients with diabetes mellitus, patients aged >/=75 years, and patien

239 ong patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acu

240 re, hypertension, age >/=75 years (doubled), diabetes mellitus, prior stroke/TIA (doubled), vascular

241 obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fat

242 us reports indicate that posttransplantation diabetes mellitus (PTDM) is associated with overall rena

243 mparing the incidence of posttransplantation diabetes mellitus (PTDM) with 2 prolonged-release tacrol

244 iatric surgery have focused on metabolic and diabetes mellitus resolution.

245 The diabetes mellitus risk was higher before than after DOTA

246 ass index (RR, 3.16; 95% CI, 1.41-7.07), and diabetes mellitus (RR, 4.19; 95% CI, 2.09-8.38).

247 mmon clinical factors, such as age, sex, and diabetes mellitus status.

248 he high coincidence ratio between HMSN-P and diabetes mellitus suggests TFG to have an important role

249 LBH gene variants are associated with type I diabetes mellitus, systemic lupus erythematosus, RA, and

250 Individuals with type 1 diabetes mellitus (T1DM) have a high risk of cardiovascu

251 glycemic control improves outcomes in type 1 diabetes mellitus (T1DM), iatrogenic hypoglycemia limits

252 ancreatic elasticity in children with type 1 diabetes mellitus (T1DM).

253 hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with

254 Type 2 diabetes mellitus (T2D) arises from a dysregulated respo

255 r the past decades, the prevalence of type 2 diabetes mellitus (T2D) has been steadily increasing aro

256 as heme iron intake, with the risk of type 2 diabetes mellitus (T2D).The Singapore Chinese Health Stu

257 (BMSCs) derived from hyperglycaemic (type 2 diabetes mellitus, T2D) and normoglycaemic mice.

258 Despite the increasing prevalence of type 2 diabetes mellitus (T2DM) among children and adolescents,

259 perglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes after 2

260 Our studies in young murine models of type 2 diabetes mellitus (T2DM) and cardiovascular disease show

261 Erythrocytes in patients with type-2 diabetes mellitus (T2DM) are associated with reduced cel

262 CC lines were identified that showed type 2 diabetes mellitus (t2DM) development and significant alv

263 tabolic profiling of individuals with type 2 diabetes mellitus (T2DM) has previously been limited to

264 een fruit consumption and the risk of type 2 diabetes mellitus (T2DM) have been inconsistent.We exami

265 Type 2 diabetes mellitus (T2DM) is a major risk factor for hear

266 findings support the hypothesis that type 2 diabetes mellitus (T2DM) is a risk factor for osteoarthr

267 le suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly

268 In type 2 diabetes mellitus (T2DM) patients (n = 38), the levels o

269 pplementation on metabolic profile in Type 2 diabetes mellitus (T2DM) patients and this might be due

270 wever, endurance trained athletes and type 2 diabetes mellitus (T2DM) patients store similar amounts

271 Compared to type 2 diabetes mellitus (T2DM) patients, Trained subjects have

272 PPARgamma is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics TZDs (thiazolidine

273 R) among Chinese American adults with type 2 diabetes mellitus (T2DM), and to compare these factors t

274 P-9 was independently associated with type 2 diabetes mellitus (T2DM), HOMA-IR and FFA.

275 rom normal glucose tolerance (NGT) to type 2 diabetes mellitus (T2DM), the role of beta-cell dysfunct

276 d heart failure risk in patients with type 2 diabetes mellitus (T2DM).

277 to play a role in the development of type 2 diabetes mellitus (T2DM).

278 ity in trials of intensive therapy in type 2 diabetes mellitus (T2DM).

279 nt of all the diabetic population has type 2 diabetes mellitus (T2DM).

280 (IAPP), a critical pathogenic step in type 2 diabetes mellitus (T2DM).

281 drug candidates for the treatment of Type 2 diabetes mellitus (T2DM).

282 ads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM).

283 n adult metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM).The longitudinal cohort consist

284 When adjusted to sex, hypertension, diabetes mellitus, target vessel, serial stenosis, and b

285 Compared with those without diabetes mellitus, they were more likely to have a histo

286 mly assigned 10 142 participants with type 2 diabetes mellitus to canagliflozin or placebo.

287 reatment deintensification in Americans with diabetes mellitus varies by glycemic control, health sta

288 italization occurred in 34% of patients with diabetes mellitus versus 22% of those without diabetes m

289 rm mortality among patients with undiagnosed diabetes mellitus was high compared to patients without

290 ved more in trials wherein the prevalence of diabetes mellitus was high.

291 Undiagnosed diabetes mellitus was prevalent among community-acquired

292 Diabetes mellitus was the most common content area for m

293 on model showed fewer teeth, higher age, and diabetes mellitus were statistically significant indepen

294 e of liver disease, liver-related death, and diabetes mellitus, whereas the other conditions studied

295 LT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascula

296 ased cohort study among patients with type 2 diabetes mellitus with established cardiovascular diseas

297 panning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk, repre

298 ta on knowledge on and practices relating to diabetes mellitus with particular emphasis on ocular iss

299 rapeutic target in the management of type II diabetes mellitus, with actions including regulation of

300 bstantial proportion of patients with type 2 diabetes mellitus without clinically recognized events h